Controlled release composition for a biologically active material dissolved or dispersed in an L2-phase
August 18, 2013. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent ReferencesMethod of preparing a controlled release liquid pharmaceutical composition Method of preparing a controlled-release pharmaceutical preparation, and resulting composition Method of encapsulating biologically active materials in lipid vesicles Method of encapsulating biologically active materials in lipid vesicles Pharmaceutical compositions for parenteral or local administration Pharmaceutical multicomponent systems and method of preparing same Composition for delivery of orally administered drugs and other substances Method and composition for controlled delivery of biologically active agents Patent #: 5143934 InventorsAssigneeApplicationNo. 107908 filed on 08/18/1993US Classes:514/786, Glyceride514/769, DESIGNATED INORGANIC NONACTIVE INGREDIENT OR ELEMENTAL MATERIAL OTHER THAN WATER514/772DESIGNATED ORGANIC NONACTIVE INGREDIENT CONTAINING OTHER THAN HYDROCARBONExaminersPrimary: Henley, III, RaymondAttorney, Agent or FirmForeign Patent References
International ClassA61K 047/00Foreign Application Priority Data1986-07-01 SEAbstractThe invention relates to a controlled-release composition for a biologically active material, wherein said active material has been dissolved or dispersed in an L2-phase comprising(a) at least one monoglyceride of an unsaturated fatty acid having 16-22 carbon atoms or a vegetable or animal oil containing such a monoglyceride,(b) at least one triglyceride of at least one unsaturated fatty acid having 16-22 carbon atoms or a vegetable or animal oil containing such triglycerides and(c) at least one polar liquid selected from the group consisting of water, glycerol, ethylene glycol and propylene glycol. Such L2 phases are known per se but are novel in this context.The composition is prepared by forming the L2 phase and adding the biologically active material before, during or after the formation of the L2-phase. For sensitive substances such as proteins a mixture of the mono- and triglycerides is added dropwisely to a solution of said substance in the polar liquid.The invention also relates to the use of this specific L2-phase to encapsulate a biologically active material.Other References
| |
